Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887668 | 0.88 | ADRB2 (0.43) | ADRB2ADRB1KMT2AMAPTCYP3A4 | |
| SCHEMBL5631067 | 0.88 | MAPT (0.44) | ADRB2ADRB1KMT2AMAPTCYP2D6 | |
| SCHEMBL5630730 | 0.88 | MAPT (0.44) | ADRB2ADRB1KMT2AMAPTCYP2D6 | |
| SCHEMBL4884792 | 0.87 | MAPT (0.39) | ADRB2ADRB1KMT2AMAPTCYP2D6 | |
| SCHEMBL4890567 | 0.87 | ABCB1 (0.49) | ADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL8265350 | 0.86 | ADRB2 (0.45) | ADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL4881168 | 0.85 | LMNA (0.41) | ADRB2ADRB1KMT2AMAPTCYP3A4 | |
| SCHEMBL7335704 | 0.83 | CYP3A4 (0.45) | ADRB2ADRB1KMT2AMAPTCYP2D6 | |
| SCHEMBL5633240 | 0.82 | LMNA (0.41) | ADRB2ADRB1KMT2AMAPTCYP2D6 | |
| SCHEMBL4890601 | 0.81 | CA12 (0.43) | ADRB2ADRB1KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | claimed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | ADRB2 4/4885ADRB1 5/4885KMT2A 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.